| Jesus E Carale, MD | |
|
1112 Carson Ave, La Junta, CO 81050-2728 | |
| (719) 383-6480 | |
| (719) 383-6412 |
| Full Name | Jesus E Carale |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 31 Years |
| Location | 1112 Carson Ave, La Junta, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043236961 | NPI | - | NPPES |
| 07370342 | Medicaid | CO | |
| CAA54671 | Other | CO | BLUE CROSS |
| P00175695 | Other | CO | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 39740 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Arkansas Valley Regional Medical Center | La junta, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Arkansas Valley Regional Medical Center | 9436062833 | 10 |
News Archive
Northwest Biotherapeutics, Inc. today announced further long-term follow-up data, for the period from January through September 2009, from its prior Phase I and Phase I/II clinical trials conducted at UCLA with DCVax®-Brain in patients with Glioblastoma multiforme ("GBM"). GBM is the most rapid and lethal type of brain cancer. During the update period, only one of the twenty patients treated with DCVax®-Brain (in addition to standard of care) died, and that patient had survived for nearly 7 years (80.5 months).
Nearly four in 10 news stories about mental illness analyzed by Johns Hopkins Bloomberg School of Public Health researchers connect mental illness with violent behavior toward others, even though less than five percent of violence in the United States is directly related to mental illness.
A study conducted by researchers at Thomas Jefferson University, Philadelphia, and published Tuesday, July 27, 2004, in the journal Neurology, shows that Frova (frovatriptan), a triptan class migraine therapy with a long half life, significantly reduced the incidence of menstrual associated migraines (MAM) in women who took the medication preventively, in advance of anticipated onset of headache.
Cardiovascular calcification is a major health concern in patients with kidney failure undergoing hemodialysis.
Merck KGaA today announced that the first patient has been enrolled in its global Phase III clinical study, START (Stimulating Targeted Antigenic Responses To NSCLC), assessing the efficacy and safety of Stimuvax (BLP25 liposome vaccine) as a potential treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC).
› Verified 1 days ago
| Entity Name | Arkansas Valley Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649449075 PECOS PAC ID: 9436062833 Enrollment ID: O20031111000685 |
News Archive
Northwest Biotherapeutics, Inc. today announced further long-term follow-up data, for the period from January through September 2009, from its prior Phase I and Phase I/II clinical trials conducted at UCLA with DCVax®-Brain in patients with Glioblastoma multiforme ("GBM"). GBM is the most rapid and lethal type of brain cancer. During the update period, only one of the twenty patients treated with DCVax®-Brain (in addition to standard of care) died, and that patient had survived for nearly 7 years (80.5 months).
Nearly four in 10 news stories about mental illness analyzed by Johns Hopkins Bloomberg School of Public Health researchers connect mental illness with violent behavior toward others, even though less than five percent of violence in the United States is directly related to mental illness.
A study conducted by researchers at Thomas Jefferson University, Philadelphia, and published Tuesday, July 27, 2004, in the journal Neurology, shows that Frova (frovatriptan), a triptan class migraine therapy with a long half life, significantly reduced the incidence of menstrual associated migraines (MAM) in women who took the medication preventively, in advance of anticipated onset of headache.
Cardiovascular calcification is a major health concern in patients with kidney failure undergoing hemodialysis.
Merck KGaA today announced that the first patient has been enrolled in its global Phase III clinical study, START (Stimulating Targeted Antigenic Responses To NSCLC), assessing the efficacy and safety of Stimuvax (BLP25 liposome vaccine) as a potential treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jesus E Carale, MD 1112 Carson Ave, La Junta, CO 81050-2728 Ph: (719) 383-6480 | Jesus E Carale, MD 1112 Carson Ave, La Junta, CO 81050-2728 Ph: (719) 383-6480 |
News Archive
Northwest Biotherapeutics, Inc. today announced further long-term follow-up data, for the period from January through September 2009, from its prior Phase I and Phase I/II clinical trials conducted at UCLA with DCVax®-Brain in patients with Glioblastoma multiforme ("GBM"). GBM is the most rapid and lethal type of brain cancer. During the update period, only one of the twenty patients treated with DCVax®-Brain (in addition to standard of care) died, and that patient had survived for nearly 7 years (80.5 months).
Nearly four in 10 news stories about mental illness analyzed by Johns Hopkins Bloomberg School of Public Health researchers connect mental illness with violent behavior toward others, even though less than five percent of violence in the United States is directly related to mental illness.
A study conducted by researchers at Thomas Jefferson University, Philadelphia, and published Tuesday, July 27, 2004, in the journal Neurology, shows that Frova (frovatriptan), a triptan class migraine therapy with a long half life, significantly reduced the incidence of menstrual associated migraines (MAM) in women who took the medication preventively, in advance of anticipated onset of headache.
Cardiovascular calcification is a major health concern in patients with kidney failure undergoing hemodialysis.
Merck KGaA today announced that the first patient has been enrolled in its global Phase III clinical study, START (Stimulating Targeted Antigenic Responses To NSCLC), assessing the efficacy and safety of Stimuvax (BLP25 liposome vaccine) as a potential treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC).
› Verified 1 days ago
Richard A Shand, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 111 W 2nd St, La Junta, CO 81050 Phone: 719-384-2771 Fax: 719-384-2077 | |
Mrs. Madhuri Bobba, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1200 Carson Ave Ste 103, La Junta, CO 81050 Phone: 719-383-5925 Fax: 719-383-5928 |